These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 19818221

  • 1. Treatment of severe psoriasis with infliximab: report of two cases.
    Peternel S, Prpić-Massari L, Guina T, Novak S, Brajac I, Kastelan M.
    Acta Dermatovenerol Croat; 2009; 17(3):204-6. PubMed ID: 19818221
    [Abstract] [Full Text] [Related]

  • 2. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J.
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [Abstract] [Full Text] [Related]

  • 3. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, Wain M, Barker JN.
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [Abstract] [Full Text] [Related]

  • 4. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
    Antoniou C, Stefanaki I, Stratigos A, Moustou E, Vergou T, Stavropoulos P, Avgerinou G, Rigopoulos D, Katsambas AD.
    Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
    [Abstract] [Full Text] [Related]

  • 5. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H, Nakagawa H, Japanese Infliximab Study investigators.
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [Abstract] [Full Text] [Related]

  • 6. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D, Morel P, Dubertret L, Bachelez H.
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [Abstract] [Full Text] [Related]

  • 7. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
    Dalaker M, Bonesrønning JH.
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):277-82. PubMed ID: 19207642
    [Abstract] [Full Text] [Related]

  • 8. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
    Puig L.
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment.
    DE Oliveira JP, Levy A, Morel P, Guibal F.
    J Dermatol; 2008 Sep; 35(9):575-80. PubMed ID: 18837702
    [Abstract] [Full Text] [Related]

  • 10. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
    Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A.
    J Am Acad Dermatol; 2004 Oct; 51(4):534-42. PubMed ID: 15389187
    [Abstract] [Full Text] [Related]

  • 11. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
    Goedkoop AY, Kraan MC, Picavet DI, de Rie MA, Teunissen MB, Bos JD, Tak PP.
    Arthritis Res Ther; 2004 Oct; 6(4):R326-34. PubMed ID: 15225368
    [Abstract] [Full Text] [Related]

  • 12. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
    Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB.
    J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H, Reich K.
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.
    Kalb RE, Gurske J.
    J Am Acad Dermatol; 2005 Oct; 53(4):616-22. PubMed ID: 16198781
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.
    Markham T, Mullan R, Golden-Mason L, Rogers S, Bresnihan B, Fitzgerald O, Fearon U, Veale DJ.
    J Am Acad Dermatol; 2006 Jun; 54(6):1003-12. PubMed ID: 16713454
    [Abstract] [Full Text] [Related]

  • 20. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
    Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A, IMPACT 2 Trial Investigators.
    Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.